These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 28835439)

  • 1. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.
    Majeed A; Ågren A; Holmström M; Bruzelius M; Chaireti R; Odeberg J; Hempel EL; Magnusson M; Frisk T; Schulman S
    Blood; 2017 Oct; 130(15):1706-1712. PubMed ID: 28835439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate.
    Sheikh-Taha M
    Intern Emerg Med; 2019 Mar; 14(2):265-269. PubMed ID: 30414056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.
    Panos NG; Cook AM; John S; Jones GM;
    Circulation; 2020 May; 141(21):1681-1689. PubMed ID: 32264698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding.
    Arachchillage DRJ; Alavian S; Griffin J; Gurung K; Szydlo R; Karawitage N; Laffan M
    Br J Haematol; 2019 Mar; 184(5):808-816. PubMed ID: 30515764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of Apixaban and Rivaroxaban Using Activated Prothrombin Complex Concentrates in Patients with Major Bleeding.
    Sheikh-Taha M; Crawley RM
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):295-299. PubMed ID: 31709499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
    Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
    J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study.
    Schulman S; Gross PL; Ritchie B; Nahirniak S; Lin Y; Lieberman L; Carrier M; Crowther MA; Ghosh I; Lazo-Langner A; Zondag M;
    Thromb Haemost; 2018 May; 118(5):842-851. PubMed ID: 29564837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-activated prothrombin complex concentrates for major bleeding in patients on apixaban and rivaroxaban.
    Sheikh-Taha M
    Intern Emerg Med; 2020 Sep; 15(6):1123-1124. PubMed ID: 31664661
    [No Abstract]   [Full Text] [Related]  

  • 9. Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban.
    Barzilai M; Kirgner I; Steimatzky A; Salzer Gotler D; Belnick Y; Shacham-Abulafia A; Avivi I; Raanani P; Yahalom V; Nakav S; Varon D; Yussim E; Bachar GN; Spectre G
    Acta Haematol; 2020; 143(3):266-271. PubMed ID: 31610537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
    Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
    Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors.
    Schulman S; Bhagirath V; Chan N; Germini F; Ikesaka R; Iorio A; Mithoowani S; Weitz JI; Gross PL
    J Thromb Haemost; 2024 Oct; 22(10):2761-2766. PubMed ID: 39002730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study.
    Sindet-Pedersen C; Staerk L; Pallisgaard JL; Gerds TA; Berger JS; Torp-Pedersen C; Gislason GH; Olesen JB
    Eur Heart J Cardiovasc Pharmacother; 2018 Oct; 4(4):220-227. PubMed ID: 29945162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Activated Prothrombin Complex Concentrate for Reversal of the Anticoagulant Effect of Apixaban and Rivaroxaban in Patients with Major Bleeding.
    Sheikh-Taha M; Clark HL; Crawley RM
    Clin Drug Investig; 2023 Nov; 43(11):883-888. PubMed ID: 37882941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis.
    Parsels KA; Seabury RW; Zyck S; Miller CD; Krishnamurthy S; Darko W; Probst LA; Latorre JG; Cwikla GM; Feldman EA
    Am J Emerg Med; 2022 May; 55():16-19. PubMed ID: 35245776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
    Sin JH; Berger K; Lesch CA
    J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
    Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
    Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.
    Baumann Kreuziger LM; Keenan JC; Morton CT; Dries DJ
    Biomed Res Int; 2014; 2014():583794. PubMed ID: 25136597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.
    Dawwas GK; Brown J; Dietrich E; Park H
    Lancet Haematol; 2019 Jan; 6(1):e20-e28. PubMed ID: 30558988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
    Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
    Song Y; Wang Z; Perlstein I; Wang J; LaCreta F; Frost RJA; Frost C
    J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.